Page 24 - Demo

Chapter 12224. Jansen-Van Der Weide MC, Gaasterland CMW, Roes KCB, et al. Rare disease registries: Potential applications towards impact on development of new drug treatments. Orphanet J. Rare Dis. 2018.25. Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. Am. J. Med. Genet. Part A 2017;173(9).26. Both P, ten Holt L, Mous S, et al. Tuberous sclerosis complex: Concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy Behav. 2018.27. Foster RH, Kozachek S, Stern M, Elsea SH. Caring for the caregivers: An investigation of factors related to well-being among parents caring for a child with smith-magenis syndrome. J. Genet. Couns. 2010.28. Van Remmerden MC, Hoogland L, Mous SE, et al. Growing up with Fragile X Syndrome: Concerns and Care Needs of Young Adult Patients and Their Parents. J. Autism Dev. Disord. 2020.29. De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J. Intellect. Disabil. Res. 2014.30. Schoufour JD, Oppewal A, Van Der Maarl HJK, et al. Multimorbidity and polypharmacy are independently associated with mortality in older people with intellectual disabilities: A 5-year follow-up from the HA-ID study. Am. J. Intellect. Dev. Disabil. 2018;123(1).31. Franz DN, Krueger DA. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. Am. J. Med. Genet. Part C Semin. Med. Genet. 2018;178(3).32. Hoytema van Konijnenburg EMM, Wortmann SB, Koelewijn MJ, et al. Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. Orphanet J. Rare Dis. 2021;16(1).33. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N. Engl. J. Med. 2019.34. Nagree MS, Scalia S, McKillop WM, Medin JA. An update on gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. 2019;19(7).35. Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): Current perspectives. Ther. Clin. Risk Manag. 2019.36. Curatolo P, Bjørnvold M, Dill PE, et al. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs 2016;76(5).37. Morrissey H, Pradhan T. Escitalopram in the treatment of anxiety in chromosome 18p deletion. J. Child Adolesc. Psychopharmacol. 2018;28(8).38. Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat. Rev. Neurol. 2019;15(3).39. van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Pediatr. Drugs 2020.40. Nikles J, Onghena P, Vlaeyen JWS, et al. Establishment of an International Collaborative Network for N-of-1 Trials and Single-Case Designs. Contemp. Clin. Trials Commun. 2021;23.41. Abrahamyan L, Feldman BM, Tomlinson G, et al. Alternative designs for clinical trials in rare diseases. Am. J. Med. Genet. Part C Semin. Med. Genet. 2016;172(4).42. Tate RL, Perdices M. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. 2019.43. OCEBM Levels of Evidence Working Group, Durieux N, Pasleau F, Howick J. The Oxford 2011 Levels of Evidence. Group 2011.44. Guyatt G, Sackett D, Adachi J, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ 1988.45. Shamseer L, Sampson M, Bukutu C, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ 2015.46. Lamont A, Lyons MD, Jaki T, et al. Identification of predicted individual treatment effects in randomized clinical trials. Stat. Methods Med. Res. 2018.Annelieke Muller sHL.indd 22 14-11-2023 09:07